Metastatic renal carcinoma comprehensive prognostic system.

Area of Science:

• Oncology
• Clinical Research
• Biostatistics

Background:

• Metastatic renal-cell carcinoma (mRCC) poses a significant challenge in cancer treatment.
• Effective prognostic systems are crucial for stratifying patients and guiding treatment decisions.

Purpose of the Study:

• To identify a comprehensive prognostic system of pretreatment clinical parameters for patients with metastatic renal-cell carcinoma.
• To develop a risk stratification model for mRCC patients undergoing cytokine-based therapies.

Main Methods:

• Kaplan-Meier survival analysis, log-rank statistics, and Cox regression were used.
• Pretreatment clinical parameters were analyzed in 425 mRCC patients.
• A multiple risk factor model was created to identify significant prognostic variables.

Main Results:

• Neutrophil count, serum lactate dehydrogenase (LDH), serum C-reactive protein (CRP), number of metastatic sites, and bone metastases were identified as key pretreatment risk factors.
• Neutrophil count emerged as the major prognostic factor (hazard ratio=1.9).
• Patients were categorized into low-, intermediate-, and high-risk groups with distinct median overall survival rates (32+, 18+, and 8+ months, respectively).

Conclusions:

• The developed prognostic system effectively stratifies mRCC patients into distinct risk groups.
• These prognostic categories aid in individual patient management and in the selection of patients for clinical trials.
• Pretreatment clinical parameters provide valuable insights into predicting outcomes for mRCC patients.